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Conjugate vaccines have reduced pneumococcal dis-
ease in vaccinated children and unvaccinated adults, 
but non-vaccine serotypes are of concern, particularly 
if antibiotic resistant. We reviewed Streptococcus 
pneumoniae collected via: (i) the British Society for 
Antimicrobial Chemotherapy (BSAC) surveillances from 
2001–2014; (ii) Public Health England’s (PHE) invasive 
isolate surveillance from 2005–2014 and (iii) referral 
to PHE for resistance investigation from 2005–2014. 
Serotype 15A increased in all series, with many rep-
resentatives showing triple resistance to macrolides, 
tetracyclines and penicillin. 15A was consistently 
among the 10 most prevalent serotypes from 2011 in 
PHE and BSAC invasive isolate/bacteraemia surveil-
lance but never previously; 26–33% of these invasive 
15A isolates had triple resistance. BSAC respiratory 
isolates were only serotyped in 2013/14 and 2014/15 
(October to September); 15A was most prevalent sero-
type in both periods, comprising 9–11% of isolates, 
38–48% of them with triple resistance. Serotype 15A 
represented 0–4% of S. pneumoniae referred to PHE 
for reference investigation annually until 2008 but 
rose to 29% (2013) and 32% (2014). Almost all multid-
rug-resistant 15A isolates were sequence type (ST) 63 
variants, whereas susceptible 15A isolates were clon-
ally diverse. The rise of serotype 15A suggests that 
pneumococcal conjugate vaccines will need ongoing 
adaptation.
Introduction
Seven-valent pneumococcal conjugate vaccine 
(Prevenar 7, PCV7) first became available internationally 
in 2000, and protects against invasive Streptococcus 
pneumoniae infection by serotypes 4, 6B, 9V, 14, 18C, 
19F and 23F. Numerous countries have reported that 
deployment reduced the incidence of invasive (i.e. 
blood and cerebrospinal fluid (CSF)) S. pneumoniae 
disease both in children, who are vaccinated, and in 
elderly adults, who benefit through reduced carriage 
and transmission of virulent serotypes by children [1-4]. 
Antibiotic resistance was historically concentrated in 
five PCV7-targeted serotypes (6B, 9V, 14, 19F and 23F) 
[5] and several countries have reported reductions in 
the prevalence of resistance as these were displaced 
[6]. United Kingdom (UK) experience conforms to these 
general patterns [7], with the caveat that penicillin-non-
susceptible S. pneumoniae were uncommon before the 
vaccine’s introduction to the childhood schedule in 
2006/07, meaning that little further fall occurred; mac-
rolide resistance was reduced, reflecting displacement 
of a resistant serotype 14 lineage [8,9].
The success of PCV7 was partly offset by rises in other 
serotypes; notably 19A, where multidrug resistance to 
antibiotics became frequent [10,11]. This was countered 
by replacing PCV7 with a 13-valent conjugate vaccine 
(PCV13), additionally covering serotypes 1, 3, 5, 6A, 7F 
and 19A. PCV13 replaced PCV7 in the UK in April 2010 
and this switch was followed by (i) reduced infant car-
riage of these additional serotypes [12], and (ii) a fur-
ther 56% reduction in invasive disease incidence from 
a post-PCV7 baseline [13]. Again, however, rises are 
being seen in other, non-vaccine, serotypes, principally 
8, 10A, 12F, 15A and 24F [13]. Serotype 15A is of particu-
lar interest since multidrug-resistant isolates belong-
ing to this serotype have been reported as far apart as 
east Asia [14-16], North America [17,18], Norway [19], 
Italy [20] and Australia [21]. Here, we explore the rise 
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Table 1
Ten most-represented pneumococcal serotypes in the British Society for Antimicrobial Chemotherapy bacteraemia 
surveillance, United Kingdom and Republic of Ireland, 2001–2014 (n = 3,206 isolates)
Serotype (bold); number and proportion of isolates % for top 10a
Rank 1 2 3 4 5 6 7 8 9 10
2001 
(n = 227)
14 8 9V 23F 3 4 6B 12F NA NA 1 9F NA
71.4%n = 36 
15.9%
n = 23 
10.1%
n = 20 
8.8%
n = 17 
7.5%
n = 15 
6.6%
n = 11 
4.8% NA NA
n = 9 
4.0% NA
2002 
(n = 220)
14 9V 6B 19F 23F NA NA 
1 22F 
8 3 
4 7F 6A 
69.5%19A 20 
n = 42 
19.1%
n = 24 
10.9%
n = 14 
6.4% NA NA
n = 11 
5.0%
n = 10 
4.5%
n = 9 
4.1%
n = 8 
3.6%
n = 7 
3.2%
2003 
(n = 239)
14 9V 1 4 8 23F 3 19F NA 6B 18C 
72.0%n = 34 
14.2%
n = 30 
12.6%
n = 21 
8.8%
n = 17 
7.1%
n = 16 
6.7%
n = 13 
5.4%
n = 11 
4.6% NA
n = 10 
4.2%
n = 6 
3.8%
2004 
(n = 241)
14 1 19F 4 23F NA 9V 8 3 7F 19A 22F NA 
67.2%n = 37 
15.4%
n = 24 
10.0%
n = 16 
6.6%
n = 14 
5.8% NA
n = 13 
5.4%
n = 13 
5.4%
n = 11 
4.6%
n = 10 
4.1% NA
2005 
(n = 230)
14 1 9V 23F 3 4 8 NA NA 19F 7F 6B 
75.2%n = 35 
15.2%
n = 30 
13.0%
n = 21 
9.1%
n = 18 
7.8%
n = 14 
6.1% NA NA
n = 10 
4.3%
n = 9 
3.9%
n = 8 
3.5%
2006 
(n = 231)
1 14 9V 23F 6A 4 6B 7F NA NA 8 18C NA
75.8%n = 36 
15.6%
n = 29 
12.6%
n = 22 
9.5%
n = 16 
6.9%
n = 15 
6.5%
n = 13 
5.6% NA NA
n = 9 
3.9% NA
2007 
(n = 216)
14 1 9V 8 7F 23F 3 4 6A NA NA 12F 
77.3%n = 30 
13.9%
n = 26 
12.0%
n = 20 
9.3%
n = 19 
8.8%
n = 14 
6.5%
13 
6.0%
n = 12 
5.6% NA NA
n = 9 
4.2%
2008 
(n = 201)
1 14 8 7F 22F NA 9V 19A 3 20 4 23F 
73.6%n = 32 
15.9%
n = 20 
10.0%
n = 17 
8.5%
n = 15 
7.5% NA
n = 14 
7.0%
n = 13 
6.5%
n = 9 
4.5%
n = 7 
3.5%
n = 6 
3.0% =
2009 
(n = 211)
7F 3 19A 8 22F 1 6A 14 12F 4 
71.6%n = 26 
12.3%
n = 23 
10.9%
n = 18 
8.5%
n = 17 
8.1%
n = 14 
6.6%
n = 13 
6.2%
n = 12 
5.7%
n = 11 
5.2%
n = 9 
4.3%
n = 8 
3.8%
2010 
(n = 249)
19A 7F 1 8 33F 22F 14 3 6A 11A NA
68.7%n = 38 
15.3%
n = 33 
13.3%
n = 21 
8.4%
n = 19 
7.6%
n = 14 
5.6%
n = 11 
4.4%
n = 10 
4.0%
n = 9 
3.6%
n = 8 
3.2% NA
2011 
(n = 230)
7F 19A 8 3 22F 1 23B 9N 15A NA 12F 19F 
70.4%n = 29 
12.6%
n = 28 
12.2%
n = 22 
9.6%
n = 19 
8.3%
n = 18 
7.8%
n = 14 
6.1%
n = 9 
3.9%
n = 8 
3.5% NA
n = 7 
3.0%
2012 
(n = 229)
7F 8 22F 19A 33F 12F 1 3 NA 6C 15A 
69.4%n = 29 
12.7%
n = 27 
11.8%
n = 25 
10.9%
n = 20 
8.7%
n = 12 
5.2%
n = 11 
4.8%
n = 10 
4.4% NA
n = 8 
3.5%
n = 7 
3.1%
2013 
(n = 235)
7F 8 NA 22F 3 19A NA 23A 12F 15A 33F NA 1 11A 24F 
66.8%n = 36 
15.3% NA
n = 15 
6.4%
n = 14 
6.0% NA
n = 10 
4.3%
n = 9 
3.8%
n = 8 
3.4% NA
n = 7 
3.0%
2014 
(n = 247)
8 22F 12F 15A 19A 3 7F 9N 24F NA 10A 
71.7%n = 43 
17.4%
n = 22 
8.9%
n = 20 
8.1%
n = 19 
7.7%
n = 16 
6.5%
n = 14 
5.7%
n = 13 
5.3%
n = 11 
4.5% NA
n = 8 
3.2%
NA: not applicable.
Green: covered by PCV7; yellow: additional types covered by PCV13; pink: not covered by any conjugate vaccine.
a When there is a tie for tenth rank, only one of the tied serotypes is counted into the percentage total for the top 10.
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of serotype 15A S. pneumoniae in the UK and Ireland at 
epidemiological and molecular levels, using data from 
both the British Society for Antimicrobial Chemotherapy 
(BSAC) and Public Health England (PHE) surveillances.
Methods
British Society for Antimicrobial 
Chemotherapy surveillance
The BSAC Bacteraemia and Respiratory Surveillance 
Programmes have been described previously [22-24]. 
Both collect isolates from across the UK and Republic 
of Ireland. The Bacteraemia programme runs on the 
calendar year. Until 2009 we asked participating lab-
oratories to send up to 10 consecutive bloodstream 
S. pneumoniae isolates per annum from each of 25 
hospital laboratories; from 2010 we have similarly 
sought seven consecutive bloodstream isolates per 
annum from each of 40 hospital laboratories. Isolates 
have been serotyped throughout, and results were 
reviewed across the years 2001 to 2014, inclusive. The 
Respiratory Programme runs on an October–September 
year, designated e.g. 2013/14, so that isolates from 
each winter peak of respiratory disease are not split 
between calendar years. It examines consecutive iso-
lates from lower respiratory tract infections (LRTIs) in 
non-hospitalised patients or those hospitalised for less 
than 48 hours. Until 2013/14 the BSAC Respiratory 
Surveillance Programme did not routinely serotype iso-
lates, therefore only 2013/14 and 2014/15 data were 
reviewed. In both these years the surveillance sought 
14 consecutive LRTI S. pneumoniae isolates from 
each of the same 40 laboratories contributing to the 
Bacteraemia surveillance. Actual numbers of isolates 
collected in both surveillances were somewhat below 
these targets (see Results) and, in most years, one or 
two recruited laboratories failed to collect, and were 
subsequently dropped and replaced by alternative 
sites. Hospital laboratory mergers, mostly in the past 5 
years, have also meant that participating microbiology 
laboratories increasingly source isolates from multiple 
hospitals, augmenting representativeness.
Public Health England invasive isolate 
surveillance
PHE Colindale routinely seeks submission of all inva-
sive (i.e. blood and CSF) S. pneumoniae from hospital 
laboratories in England, Wales and Northern Ireland, 
receiving ca 4,000–5,000 isolates each year), over 
95% of them from blood. Results of this surveillance 
were reviewed from 2005 (i.e. 1 year before PCV7 was 
introduced) to 2014. Susceptibility testing is performed 
on a subset of these isolates, comprising all those from 
laboratories contributing to European Antimicrobial 
Resistance Surveillance (EARS)-net [25]; this total fluc-
tuated between 1,159 and 2,066 organisms annually 
over the study period.
Public Health England reference laboratory 
submissions
Besides surveillance isolates from invasive infections, 
PHE receives variable numbers of S. pneumoniae as 
reference submissions from respiratory and other non-
sterile sites, principally eye and ear infections. Most 
are sent for investigation because the sender perceives 
them to have unusual resistance patterns, although 
senders’ definitions of unusual vary and may be contin-
gent on the site of the infection. Over 95% of isolates 
are from laboratories in England, Wales and Northern 
Ireland, with the remaining ca 5% largely from Scotland 
and the Republic of Ireland. Data were reviewed across 
the period 2005 to 2014.
Identification, serotyping and susceptibility 
testing
All surveillance and referred isolates were confirmed 
as forming alpha-haemolytic colonies on horse blood 
agar and being inhibited by a 5 µg optochin (ethylhy-
drocupreine hydrochloride) disc (Oxoid-Thermofisher, 
Basingstoke, UK). Isolates with atypical colonial mor-
phology, or which could not be serotyped (below), 
were confirmed as being lysed within 30 min by 2% 
sodium deoxycholate, and being catalase-negative 
when tested with 3% hydrogen peroxide. For sero-
typing, isolates were grown overnight in Todd Hewitt 
broth at 35 °C with 5% CO2, harvested by centrifuga-
tion at 453 g for 30 min, then re-suspended in a small 
residual volume of broth and subjected to slide agglu-
tination tests with standard antisera (Statens Serum 
Institut, Copenhagen, Denmark) [26]. Agar dilution 
susceptibility tests were performed in accordance with 
BSAC guidelines [27], using IsoSensitest agar (Oxoid-
Thermofisher) supplemented with 5% defibrinated 
horse blood and incubated at 35–37 °C in a 5% CO2 
atmosphere. ‘Triple resistance’ was defined as resist-
ant to erythromycin (minimum inhibitory concentration 
(MIC) > 0.5 mg/L) and tetracycline (MIC > 2 mg/L), and 
non-susceptible to penicillin (MIC > 0.06 mg/L), based 
on EUCAST breakpoints [28])
DNA extraction, sequencing and bioinformatic 
analysis
Isolates were grown on horse blood agar (PHE Media 
Services) and treated by the Qiagen-recommended 
method for lysis of Gram-negative bacteria (Qiagen, 
Manchester, UK), which is effective for S. pneumoniae 
and simpler than the Gram-positive protocol. DNA was 
extracted from the lysates using a QIAsymphony SP 
automated instrument (Qiagen) and a QIAsymphony 
DSP DNA Mini Kit, using a tissue extraction protocol. 
DNA concentrations were measured using the Quant-IT 
Broad Range DNA Kit (Life Technologies, Paisley, UK) 
and GloMax 96 Microplate Luminometer (Promega, 
Southampton, UK). After adjusting to a concentra-
tion of 10–30 ng/μl, DNA was sent for whole genome 
sequencing (WGS) by Illumina methodology. The result-
ing data were automatically analysed using a bespoke 
bioinformatic pipeline for S. pneumoniae, developed 
by PHE. Among other things, this (i) checks species 
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identification by a kmer method and (ii) automati-
cally assigns MLST sequence types (STs), identified 
by mapping the reads against all S. pneumoniae allele 
variants held in the MLST database [29], using a modi-
fication of the short-read sequence typing (SRST) soft-
ware [30]. Resistance genes affecting susceptibility for 
macrolides and tetracyclines were identified, and their 
sequences reviewed.
Results
Serotype trends, British Society for 
Antimicrobial Chemotherapy bacteraemia 
surveillance
Prior to widespread UK deployment of PCV7 in the 
2006/07 season, S. pneumoniae belonging to its tar-
get serotypes accounted for around half (44.4–53.6% 
in each of the years 2001 to 2006 inclusive) of all the 
S. pneumoniae collected in the BSAC bacteraemia sur-
veillance but these declined to 4.7% of isolates by 2013 
and 2.0% in 2014. Serotype 14 was the most common 
type in 6 of the 7 years from 2001 to 2007, compris-
ing 13–20% of all isolates (Table 1) and accounting for 
61% of all erythromycin-resistant isolates. By 2013, 
however, serotype 14 had only a single representative 
(0.4%), and none in 2014. Other serotypes became 
relatively more frequent as the PCV7 types declined, 
notably 7F and 19A, whereas serotype 1 had been 
expanding since 2001. These three types are within the 
spectrum of PCV13 and have declined, with variable 
rapidity, following its replacement of PCV7 in 2010. A 
further PCV13 type, serotypes 3, shows much less evi-
dence of decline, as also noted elsewhere [13].
Serotype 15A isolates were encountered in each year 
from 2010 and the serotype was in the top 10 from 2011 
onwards, whereas previously the type was sporadic. 
Other types that had long been encountered at mod-
erate to low prevalence also became more prominent, 
Table 2
Major serotypes and associations with resistance among Streptococcus pneumoniae from the British Society for 
Antimicrobial Chemotherapy Respiratory Surveillance, United Kingdom and Republic of Ireland, 2013/14 and 2014/15 
(n=805)
Serotype October 2013 to September 2014 October 2014 to September 2015
Count % of total isolates No (%) with triple resistance Count % of total isolates 
No (%) with 
triple resistance 
15A 34 9.1 13 (38.2%) 46 10.7 22 (47.8%)
23B 26 6.9 1 (3.8%) 21 4.9 0
3 22 5.9 0 26 6.0 0
11A 21 5.6 1 (4.8%) 34 7.9 1 (2.9%)
23A 21 5.6 0 30 7.0 4 (13.3%)
22F 19 5.1 0 17 4.0 0
6C 18 4.8 0 12 2.8 0
19A 17 4.5 5 (29.4%) 14 3.3 4 (28.6%)
24F 16 4.3 0 12 2.8 1 (8.3%)
35F 14 3.7 0 14 3.3 0
10A 14 3.7 0 12 2.8 0
31 14 3.7 0 16 3.7 0
16F 12 3.2 1 (8.3%) 19 4.4 0
15B 11 2.9 0 3 0.7 0
17F 11 2.9 0 16 3.7 0
19F 11 2.9 3 (27.3%) 14 3.3 5(35.7%)
35B 11 2.9 0 18 4.2 0
8 10 2.7 0 12 2.8 1 (8.3%)
Other 
serotypes, 
with < 10 isolates 
in one or both 
years
73 19.4 3 (4.9%)a 85 (21.7) 10 (2.3%)a
PCV7 serotypes 17 4.5 NA 20 4.6 NA
PCV13 serotypes 63 16.8 NA 67 15.6 NA
Total 375 100 27 (7.2%) 430 100 49 (11.4%)
NA: not applicable; PCV: pneumococcal conjugate vaccine.
a In 2013/14, three 6B isolates had triple resistance; the 10 ‘Other serotype’ isolates with triple resistance in 2014/15 comprised three non-
typeable, two 12F and single representatives of 6B, 7F, 9N 9V and 23.
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including serotypes 8, and (albeit with considerable 
year-on-year variation) 22F.
Triple resistance was seen in just 60/3,206 isolates 
(1.97%) throughout the period reviewed and its preva-
lence exceeded 10% only among isolates of serotypes 
37 (2/3 isolates), 6B (13/90 isolates, 14.4%) and, most 
strikingly, 15A (13/50, 26.0%). Triple-resistant serotype 
15A S. pneumoniae were received in every year from 
2011, although never previously. This observation, 
along with increasing numbers of 15A isolates among 
PHE reference submissions (below), prompted the pre-
sent analysis.
Serotypes among British Society for 
Antimicrobial Chemotherapy respiratory 
isolates
Unlike those collected in the BSAC Bacteraemia 
Surveillance, S. pneumoniae from the BSAC Respiratory 
Surveillance were not routinely serotyped until 2013/14, 
when 15A proved to be the most frequent serotype 
(Table 2), comprising 34 9.1% of all 375 isolates col-
lected, with a similar pattern in 2014/15, when 15A 
comprised 46/430 (10.7%) of isolates. What is more, 
15A was one of only four serotypes (the others being 
6B, 19A and 19F) where triple resistance was seen 
in over 10% of representatives. Overall, triple resistance 
was seen in 13/34 (38.2%) serotype 15A isolates vs 
Table 3
Predominant serotypes among S. pneumoniae serotyped by the Respiratory and Vaccine Preventable Bacteria Reference 
Unit, Public Health England from invasive infections, 2005–2014 (n = 45,645)
Serotype (bold) number and proportion of isolates Proportion for top 
10Rank 1 2 3 4 5 6 7 8 9 10
2005 
n = 4,662
14 1 8 9V 4 23F 3 6B 7F 19F 
73.3%701 528 357 333 327 271 250 248 208 195
15.0% 11.3% 7.7% 7.1% 7.0% 5.8% 5.4% 5.3% 4.5% 4.2%
2006 
n = 4,857
14 1 9V 8 23F 4 3 6B 7F 19F 
72.1%660 611 337 321 300 288 268 256 249 210
13.6% 12.6% 6.9% 6.6% 6.2% 5.9% 5.5% 5.3% 5.1% 4.3%
2007 
n = 4,673
1 14 9V 8 7F 3 4 6A 23F 6B 
69.1%583 449 351 348 316 278 238 237 231 197
12.5% 9.6% 7.5% 7.4% 6.8% 5.9% 5.1% 5.1% 4.9% 4.2%
2008 
n = 4,978
1 7F 8 3 22F 19A 6A 14 9V 23F 
66.4%592 474 372 359 328 307 239 238 206 189
11.9% 9.5% 7.5% 7.2% 6.6% 6.2% 4.8% 4.8% 4.1% 3.8%
2009 
n = 5,000
7F 1 19A 3 22F 8 6A 12F 14 33F 
67.7%553 501 490 438 423 393 189 148 131 118
11.1% 10.0% 9.8% 8.8% 8.5% 7.9% 3.8% 3.0% 2.6% 2.4%
2010 
n = 4,881
7F 19A 1 3 8 22F 33F 6C 12F 11A 
69.9%675 640 445 362 362 361 164 161 139 102
13.8% 13.1% 9.1% 7.4% 7.4% 7.4% 3.4% 3.3% 2.8% 2.1%
2011 
n = 4,549
7F 19A 8 1 3 22F 12F 33F 6C 15A 
71.8%665 538 424 391 382 348 139 131 126 124
14.6% 11.8% 9.3% 8.6% 8.4% 7.7% 3.1% 2.9% 2.8% 2.7%
2012 
n = 4,092
7F 8 19A 22F 3 1 15A 33F 6C 12F 
68.2%485 456 369 357 276 243 176 155 148 125
11.9% 11.1% 9.0% 8.7% 6.7% 5.9% 4.3% 3.8% 3.6% 3.1%
2013 
n = 3,995
8 7F 22F 19A 3 15A 12F 1 24F 33F 
66.4%545 415 320 293 274 203 174 153 141 134
13.6% 10.4% 8.0% 7.3% 6.9% 5.1% 4.4% 3.8% 3.5% 3.4%
2014 
n = 3,959
8 12F 22F 3 19A 15A 7F 9N 33F 24F 
67.9%599 336 334 243 229 224 219 170 168 167
15.1% 8.5% 8.4% 6.1% 5.8% 5.7% 5.5% 4.3% 4.2% 4.2%
PCV: pneumococcal conjugate vaccine.
Green: covered by PCV7.
Yellow: additional types covered by PCV13.
Pink: not covered by any conjugate vaccine.
99% of isolates are from England, Wales and Northern Ireland, with the remaining few from Scotland, Crown Dependencies, Republic of 
Ireland and elsewhere.
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14/341 (4.1%) of all other isolates in 2013/14 (p < 0.001, 
logistic regression adjusted for clustering by centre); 
there was an even sharper difference, 24/46 (52.2%) 
vs 25/384 (6.5%) (p <0.001), in 2014/15.
Also notable was the fact that PCV7 serotypes 
accounted for only 17/375 (4.5%) of all the respiratory 
S. pneumoniae in 2013/14 and PCV13 types for just 
63/375 (16.8%); corresponding figures in 2014/15 were 
18/430 (4.3%) for PCV7 types and 68/430 (15.8%) for 
PCV13 types. The sole previous season when S. pneu-
moniae from the Respiratory Programme were typed 
was 2005/06, immediately before UK introduction 
of PCV7 [24]. Then, among 749 isolates, 312 (41.7%) 
belonged to PCV7 types and 450 (60.1%) to PCV13 types 
(assuming all serogroup 7 isolates belonged to sero-
type 7F) whereas 36 (4.8%) belonged to serogroup 15, 
which was not split to its component (15A/B/C/F) sero-
types. The declines in PCV7 types, PCV13 types, and 
the rise in serotype 15A (compared with all serotype 15 
in 2005/06) were all highly significant (p < 0.001, logis-
tic regression adjusted for clustering by centre).
Serotype trends, Public Health England 
invasive isolate surveillance
PHE surveillance of invasive S. pneumoniae indicated 
dramatic changes in serotype prevalence over time, as 
reviewed previously [7,13], with these paralleling the 
shifts seen for BSAC bacteraemia isolates. Specifically, 
in each of the years up to and including 2007, five or six 
of the top 10 serotypes were PCV7 types, with serotype 
14 the most abundant (Table 3), as in the BSAC series 
(Table 1). After 2007, PCV7 types declined, with none in 
the top 10 after 2009. Several of the additional types 
covered by PCV13, notably 3, 6A, 7F and 19A, became 
relatively more prominent from 2006 until 2011 while 
serotype 1, also a PCV13 additional type, was promi-
nent even before 2011. Except for serotype 3, which 
showed little convincing trend, these additional PCV13 
types declined in rank after 2010/11, with the peaking 
of serotypes 1 and 19A being especially marked.
As in the BSAC series, serotype 15A first appeared in 
the top 10 in 2011. It then advanced to seventh rank by 
2012 and sixth rank in both 2013 and 2014, account-
ing for 5.7% of isolates (224/3,959) in the latter year. 
Again, the proportion of resistance was striking: among 
the 330 tested, fully 104 (31.5%) of bloodstream 15A 
S. pneumoniae for all years pooled had triple resist-
ance, whereas triple resistance rates for all other iso-
lates that ever featured in the top 10 were under 12.5% 
(Table 4). Proportions of serotype 15A isolates, taking 
2005–2014 pooled, rose with the patient’s age, from 
1.3% in the 0–5 year age group to 1.4% in the 6–35 year 
age group, 0.6% in the 36–45 year age group, 1.7% in 
the 46–55, 56–65 and 66–75 year age groups, reaching 
2.4% in the 76–85 year age group and 3.1% among the 
over-85-year-olds (p < 0.001). Triple resistance was rep-
resented among serotype 15A S. pneumoniae through-
out the surveillance period reviewed, with proportions 
as follows: 2005, 0/3 isolates with triple resistance; 
2006, 1/4; 2007, 2/10; 2008, 4/13; 2009 7/13; 2010, 
18/34; 2011, 10/33; 2012, 15/50; 2013, 19/63 and 2014, 
33/114.
The isolates tested for antibiotic susceptibility and 
resistance (n = 13,551, annual range 1,159–2,966 p.a.) 
are a subset of those in Table 3 and comprise all iso-
lates from hospitals that participate in the EARS-net 
surveillance along with those bloodstream isolates 
where the referring laboratory specifically sought sus-
ceptibility testing. Inclusion of the latter group may 
over-represent resistant organisms, although there 
is no reason why it should do so disproportionately 
within particular serotypes.
Serotype trends, isolates referred to Public 
Health England for investigation of resistance
Between 2005 and 2014, 1,536 S. pneumoniae from 
respiratory, ear and eye infections were referred to PHE 
(Table 5) for investigation of unusual resistance. These 
submissions constitute a heavily biased sample and 
lack a denominator, but do provide a rolling snapshot 
of S. pneumoniae isolates that sending laboratories 
Table 4
Proportions of isolates with triple resistance to penicillin, 
erythromycin and tetracycline among frequent serotypes 
of Streptococcus pneumoniae from blood and cerebrospinal 
fluid infections, Public Health England surveillance, 
2005–2014 (n = 13,551)
Serotype Total Triple resistance % Triple resistance
15A 330 104 31.5
6B 420 51 12.1
19F 401 45 11.2
19A 987 83 8.4
23F 360 15 4.2
24F 124 5 4.0
9V 562 19 3.4
14 1,145 27 2.4
6A 366 3 0.8
8 1,197 3 0.3
6C 205 2 1.0
9N 261 1 0.4
3 777 2 0.3
33F 239 2 0.8
1 1,195 1 0.1
22F 761 1 0.1
12F 474 1 0.2
4 334 0 0
7F 1,155 0 0
All others 2,258 0 0
All isolates 
and serotypes 13,551 469 3.5
99% of isolates are from England, Wales and Northern Ireland, 
with the remaining few from Scotland, Crown Dependencies, 
Republic of Ireland and elsewhere.
Serotypes that reached a top-10 ranking in any surveillance year in 
Table 3 are line-listed.
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(mostly in England and Wales) consider to be concern-
ing. Overall, 896/1,536 (58.3%) had triple resistance. In 
the earlier years members of serotypes 19F, 9V, 6B and 
14 dominated, collectively accounting for 82.8–92.4% 
of referrals from 2005 to 2007, before declining from 
the start of the ‘PCV7 era’. Serotype 19A accounted for 
a growing proportion of referrals from 2005, peaking 
at 23.3% in 2011, while serotype 15A represented just 
0–4% of submissions throughout the period 2005 to 
2008 but thereafter increased progressively, becom-
ing the most commonly referred serotype in 2012. In 
2013, it accounted for 31/92 of all submissions where 
typing was undertaken, and for 31/107 in 2014. These 
proportions were greater than ever previously achieved 
by any other serotype. Fully 83.0% of serotype 15A iso-
lates (137/165) had the triple resistance vs 68.9–80.0% 
among serotype 9V, 19A and 19F referrals, with lower 
proportions for other serotypes (Table 4).
Genomic sequencing and phenotypes of 
serotype 15A isolates
Genomic sequencing was performed on 156 serotype 
15A S. pneumoniae. These represented a diversity of 
resistance patterns, and including 50 with triple resist-
ance; a limitation was that all 156 sequenced isolates 
dated from 2013 and 2014. MLST types were deduced 
from the sequence data, and 78 (50%) of the isolates 
were identified as belonging to ST63 (n = 61) or its 
single or double locus variants (n = 17). All of these 78 
ST63-related isolates were resistant to erythromycin 
(also clindamycin, not shown) and 49 (62.8%) had the 
triple resistance profile (Table 6). The macrolide and 
clindamycin resistance correlated with the consistent 
presence of erm(B) genes, as detected by WGS. All 78 
ST63-related isolates were found also to carry the tet-
racycline-resistance determinant, tet(M); those (n = 65, 
83.3%) that expressed tetracycline resistance had the 
intact gene, whereas those (n = 13, 16.7%) that were 
tetracycline-susceptible (all of them classical ST63 iso-
lates) had a deletion of two nucleotides at codon 339, 
generating a premature stop codon and thereby inac-
tivating the gene. Most of the 49 isolates with triple 
resistance were susceptible to alternative agents: 37 
remained susceptible to ampicillin, 47 to moxifloxacin, 
48 to cefotaxime and all 49 to vancomycin, all based 
on EUCAST breakpoints. Sequence types (STs) 3811 
(n = 19), 58 and its single locus variants (SLVs) (n = 21), 
and 73 and its SLVs (n = 11) were all heavily represented 
among the 78 ST63-unrelated serotype 15A isolates 
and, among all these, just one isolate had triple resist-
ance and three or fewer were non-susceptible to any 
one of erythromycin, tetracycline or penicillin.
WGS data were available for a further 141 non-15A S. 
pneumoniae, predominantly investigated owing to mul-
tidrug resistance. Six had ST63-related profiles and 
Table 5
Predominant serotypes among respiratory, ear and eye isolates of Streptococcus pneumoniae received by the Public Health 
England Colindale reference service, 2005–2014 (n=1,536)
Number of isolates of indicated serotype in year:
Grand total No with triple resistance
% with triple 
resistance2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Serotype 19F 15 31 41 50 55 35 23 14 12 14 290 232 80.0
Serotype 19A 2 10 15 27 45 44 28 17 8 17 213 169 79.3
Serotype 15A 0 4 3 8 23 22 17 26 31 31 165 137 83.0
Serotype 6B 5 18 39 35 25 13 4 7 3 2 151 104 68.9
Non-typeable rough 3 8 16 23 33 18 10 15 5 2 133 81 60.9
Serotype 9V 7 36 25 15 18 10 0 0 1 2 114 16 14.0
Serotype 14 9 18 21 6 11 11 4 2 3 1 86 30 34.9
Serotype 23F 7 9 6 16 16 9 3 2 1 3 72 35 48.6
Serotype 35B 1 3 4 9 7 6 9 4 7 4 54 9 16.7
No serotype data 1 2 0 0 0 6 1 1 5 26 42 22 52.4
Serotype 6A 0 3 5 5 3 6 1 2 0 1 26 7 26.9
Serotype 11A 0 0 1 1 4 3 3 5 2 4 23 12 52.2
Serotype 3 0 1 3 0 3 4 1 2 4 3 21 3 14.3
Serotype 1 0 0 1 2 3 5 1 1 1 0 14 1 7.1
Serotype 13 0 2 0 1 6 1 0 0 1 0 11 0 0.0
All other typesa 8 5 5 9 16 17 15 10 13 23 121 38 31.4
Total 58 150 185 207 268 210 120 108 97 133 1,536 896 58.3
15A as % typed 
reference submissionsb 0.0 2.7 1.6 3.9 8.6 10.8 14.3 24.3 33.7 29.0 11.0
95% of isolates were from England, Wales and Northern Ireland with the remainder from Scotland, Crown Dependencies, Republic of Ireland or 
elsewhere.
a Not accounting for > 10 isolates in total over the surveillance period.
b Excludes ‘no data row’ above from denominator.
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these all had triple resistance; three expressed sero-
type 19F, one serotype 21 and one 23F; the final iso-
late was typed using antisera as serotype 20 but was 
predicted to be serotype 11A based on WGS; review 
suggests that the original serotype determination was 
in error. The association with 19F (a PCV7 serotype) is 
notable (see Discussion), but members of this sero-
type were highly variable in terms of ST; among a total 
of 25 serotype 19F isolates sequenced, 22 with triple 
resistance, we recorded 12 different known STs, along 
with two new variants. No single ST had more than four 
representatives.
Discussion
Deployment of PCVs has had clear public health ben-
efits. The incidence of invasive pneumococcal disease 
has been reduced not only in vaccinated children, but 
also in elderly adults, who benefit from herd immu-
nity [31]. There is also evidence of impact on non-
invasive disease: thus, PCV7 deployment in the UK in 
2006 also was followed by a 19% reduction in hospital 
admissions for community-acquired pneumonia (CAP) 
among children aged < 2 years, reversing a rising trend 
that had persisted during the preceding decade [32]. A 
similar reduction was reported in Italy [33]. Moreover, 
a Cochrane review concluded that PCV7 reduced the 
incidence of acute otitis media in healthy vaccinated 
children, although with less impact for those with a 
history of the illness or deemed to be ‘high risk’ [34]. 
Lastly, active PCV13 vaccination was recently shown 
to achieve a 50% reduction in the incidence of bacte-
raemia and non-invasive pneumonia in elderly adults, 
again reflecting displacement of vaccine serotypes 
[35].
A limitation to this pattern of successes is, however, 
that the PCV vaccines cover only the most prevalent 
pneumococcal serotypes, leaving scope for expansion 
of other types. Deployment of PCV7 was followed by 
increased prevalence of serotype 19A isolates, many 
of them multidrug-resistant, and, although serotype 
19A is now covered by PCV13, a niche may be created 
for yet further types. Internationally, several groups 
have remarked on the increased prevalence of multi-
drug-resistant serotype 15A and 35B isolates [14-21] 
and a recent PHE analysis of invasive pneumococcal 
infections, using the data series of Table 3, noted 15A 
to be among several serotypes now increasing in num-
bers and proportion in the UK [13]. The present analysis 
extends these findings, confirming that serotype 15A S. 
pneumoniae are of growing importance, as also shown 
(i) in the BSAC bacteraemia series (Table 1), which 
overlaps the PHE series but also includes Scotland and 
Ireland, (ii) the BSAC series LRTI (Table 2), which is the 
sole UK surveillance to test S. pneumoniae from their 
predominant disease setting, and (iii) among PHE refer-
ence submissions, which provide a rolling snapshot of 
resistance phenotypes causing concern to microbiolo-
gists at sending laboratories, which are predominantly 
in England, Wales and Northern Ireland, although 
with a few isolates received from elsewhere (Table 5). 
By 2013 and 2014, serotype 15A was consistently (i) 
among the top 10 serotypes in both the PHE and BSAC 
surveillances of invasive S. pneumoniae (Tables 1 and 
3), (ii) was the top serotype among respiratory isolates 
(Table 2) and (iii) accounted for almost one third of all 
the S. pneumoniae sent for reference investigation as 
‘unusually’ resistant. Critically, and unlike other rising 
pneumococcal serotypes (8, 10A, 11A, 12F, and 24F –
see Tables 1, 3 and ref [13]) serotype 15A isolates were 
commonly resistant or non-susceptible to multiple anti-
biotics, including macrolides, clindamycin, tetracycline 
and penicillin. While none of the surveillances captures 
clinical outcomes, the fact that serotype 15A is rising 
in invasive infections implies that these organisms are 
virulent.
Around one third of serotype 15A isolates had ‘triple 
resistance’ (i.e. to macrolides and tetracycline together 
with intermediate penicillin resistance), a higher pro-
portion than for other serotypes (Table 4). This propor-
tion did not change substantially over time (although 
assessment is complicated by small total numbers of 
isolates in the earlier years), indicating that the sero-
type was gaining prominence both generally and as a 
resistant type, again implying that the surface polysac-
charides of serotype 15A support virulence.
Triple resistance among serotype 15A isolates was 
strongly associated (p < 0.0001, Fisher’s exact of chi-
squared tests) with ST63 and its variants and extremely 
rare among serotype 15A isolates belonging to other 
Table 6
Sequence types in relation to resistance of serotype 15A Streptococcus pneumoniae subjected to genomic sequencing 
(n = 156)
Number (%) non-susceptible (intermediate or resistant)
n Erythromycin Tetracycline Penicillin Triple resistance
ST63 61 61 (100%) 48 (78.7%) 46 (75.4%) 35 (57.4%)
ST63 SLV and DLV 17 17 (100%) 17 (100%) 14 (82.4%) 14 (82.4%)
Other 15Aa 78 2 (2.6%) 3 (3.8%) 1 (1.3%) 1 (1.3%)
SLV: single locus variant; ST: sequence type.
a  Includes 21 ST58 and SLVs, 19 ST3811, 11 ST73 and SLVs and 27 isolates belonging to sequence types with four representatives or fewer.
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STs. This association between serotype 15A, ST63 and 
multidrug-resistance has been made by others too 
[18,36,37] and it was suggested by Frazao et al. [38] 
that multidrug-resistant ST63–15A organisms arose by 
type transformation of ST63 strains previously express-
ing the 19F capsular serotype. The present results pro-
vide very little support for this hypothesis. Although 
3/22 multidrug-resistant serotype 19F S. pneumoniae 
examined were ST63 single- or double-locus variants, 
the remaining 19/22 belonged to diverse sequence 
types; moreover, ST63 alleles have been reported to 
be associated with other serotypes besides 19F and 
15A, including serotype 8 in Spain [39], where it is sug-
gested that they may have arisen via serotype switch-
ing of earlier Sweden 15A lineages [40].
In summary, the present findings imply that conjugate 
vaccines will face an ongoing game of ‘catch-up’, as 
new serotypes rise to prominence, and that expansion 
beyond a 13-valent formulation will be needed. They 
are pertinent also to the debate as to whether PCV13 
should be adopted for prophylactic vaccination against 
pneumonia in the elderly, as is advocated based on 
recent positive trial results in the Netherlands [35]. 
Such positive findings must be set against the fact 
that PCV13 strains now account for less than 20% of 
community-onset pneumococcal pneumonias in the UK 
(Table 2).
While the rise of any new multidrug-resistant type is 
of concern for patient management, the ST63–15A S. 
pneumoniae had high level resistances only to mac-
rolides, clindamycin and tetracyclines; MICs of penicil-
lin mostly remained in the range 0.12 to 0.5 mg/L, and 
this level of ‘non-susceptibility’ is unlikely to compro-
mise outcomes, except in meningitis. Susceptibility to 
moxifloxacin and cefotaxime remained near-universal, 
and ampicillin MICs were twofold below those of peni-
cillin, remaining in the susceptible range and revers-
ing the usual pattern for penicillin-non-susceptible 
S. pneumoniae, where ampicillin MICs mostly exceed 
those of penicillin. Treatment of infections therefore 
is unlikely to present especial problems, unless mac-
rolides or tetracyclines are used alone, for example in 
beta-lactam allergic patients.
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